<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="theme" content="hugo-academic">
  <meta name="generator" content="Hugo 0.56.3" />
  <meta name="author" content="Kaspar Rufibach">

  
  
  
  
    
      
    
  
  <meta name="description" content="Obinutuzumab is a second-generation anti-CD20 antibody targeted to improve outcome in three major lymphoma indications. In 2011, Roche launched a full development program for Obinutuzumab with four randomized Phase 3 trials, all with progression-free survival (PFS) as primary endpoint. Each of these trials compared Obinutuzumab plus an indication-specific chemotherapy against the standard of care, Rituximab plus the same chemotherapy. At the time, only a preliminary analysis of a randomized Phase 2 study in one of the indications comparing monotherapy only and assessing response instead of PFS was available. We discuss how an initial assesssment of Bayesian Predictive Power (BPP) was put together in this setup, by synthesizing information on the response-PFS association and prior assumptions. We further illustrate how this initial BPP was then updated (or not) at key study or program milestones such as read-out of one of the trials in another indication or not stopping a trial at a futility or efficacy interim analyses. BPP is generally used to inform the probability of success (PoS), a number with wide-ranging impact in our company such as valuation of the pipeline, gating of decisions by senior management, planning manufacturing capacity, or allocation of resources. We conclude by sharing experiences and recommendations on how to manage and communicate PoS updating throughout an entire development program.">

  
  <link rel="alternate" hreflang="en-us" href="https://numbersman77.netlify.com/talk/invited/2017_3_vienna_cen/">

  


  

  
  
  <meta name="theme-color" content="#0095eb">
  
  
  
  
    
  
  
    
    
      
        <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
      
    
  
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha512-6MXa8B6uaO18Hid6blRMetEIoPqHf7Ux1tnyIQdpt9qI5OACx7C+O3IVTr98vwGnlcg0LOLa02i9Y1HpVhlfiw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.1/css/academicons.min.css" integrity="sha512-NThgw3XKQ1absAahW6to7Ey42uycrVvfNfyjqcFNgCmOCQ5AR4AO0SiXrN+8ZtYeappp56lk1WtvjVmEa+VR6A==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha512-SfTiTlX6kk+qitfevl/7LibUOeJWlt9rbyDn92a1DqWOw9vWG2MFoays0sgObmWazO5BQPiFucnnEAjpAB+/Sw==" crossorigin="anonymous">
  
  
  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700%7cRoboto:400,400italic,700%7cRoboto&#43;Mono">
  
  <link rel="stylesheet" href="/styles.css">
  

  

  
  <link rel="alternate" href="https://numbersman77.netlify.com/index.xml" type="application/rss+xml" title="Kaspar Rufibach">
  <link rel="feed" href="https://numbersman77.netlify.com/index.xml" type="application/rss+xml" title="Kaspar Rufibach">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="https://numbersman77.netlify.com/talk/invited/2017_3_vienna_cen/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="twitter:site" content="@numbersman77">
  <meta property="twitter:creator" content="@numbersman77">
  
  <meta property="og:site_name" content="Kaspar Rufibach">
  <meta property="og:url" content="https://numbersman77.netlify.com/talk/invited/2017_3_vienna_cen/">
  <meta property="og:title" content="Evolvement of assurance over the lifecycle of several Phase 3 trials in a large oncology clinical development program | Kaspar Rufibach">
  <meta property="og:description" content="Obinutuzumab is a second-generation anti-CD20 antibody targeted to improve outcome in three major lymphoma indications. In 2011, Roche launched a full development program for Obinutuzumab with four randomized Phase 3 trials, all with progression-free survival (PFS) as primary endpoint. Each of these trials compared Obinutuzumab plus an indication-specific chemotherapy against the standard of care, Rituximab plus the same chemotherapy. At the time, only a preliminary analysis of a randomized Phase 2 study in one of the indications comparing monotherapy only and assessing response instead of PFS was available. We discuss how an initial assesssment of Bayesian Predictive Power (BPP) was put together in this setup, by synthesizing information on the response-PFS association and prior assumptions. We further illustrate how this initial BPP was then updated (or not) at key study or program milestones such as read-out of one of the trials in another indication or not stopping a trial at a futility or efficacy interim analyses. BPP is generally used to inform the probability of success (PoS), a number with wide-ranging impact in our company such as valuation of the pipeline, gating of decisions by senior management, planning manufacturing capacity, or allocation of resources. We conclude by sharing experiences and recommendations on how to manage and communicate PoS updating throughout an entire development program.">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2018-01-11T00:00:00&#43;01:00">
  
  <meta property="article:modified_time" content="2018-01-11T00:00:00&#43;01:00">
  

  

  <title>Evolvement of assurance over the lifecycle of several Phase 3 trials in a large oncology clinical development program | Kaspar Rufibach</title>

</head>
<body id="top" data-spy="scroll" data-target="#toc" data-offset="71" >

<nav class="navbar navbar-default navbar-fixed-top" id="navbar-main">
  <div class="container">

    
    <div class="navbar-header">
      
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
              data-target=".navbar-collapse" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      
      <a class="navbar-brand" href="/">Kaspar Rufibach</a>
    </div>

    
    <div class="collapse navbar-collapse">

      
      
      <ul class="nav navbar-nav navbar-left">
        

        

        
          
        

        <li class="nav-item">
          <a href="/#about">
            
            <span>Home</span>
            
          </a>
        </li>

        
        

        

        
          
        

        <li class="nav-item">
          <a href="/#publications">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        

        
          
        

        <li class="nav-item">
          <a href="/#software">
            
            <span>Software</span>
            
          </a>
        </li>

        
        

        

        
          
        

        <li class="nav-item">
          <a href="/#talks">
            
            <span>Talks</span>
            
          </a>
        </li>

        
        

        

        
          
        

        <li class="nav-item">
          <a href="/#teaching">
            
            <span>Teaching &amp; supervision</span>
            
          </a>
        </li>

        
        

        

        
          
        

        <li class="nav-item">
          <a href="/#working">
            
            <span>Working groups</span>
            
          </a>
        </li>

        
        

        

        
          
        

        <li class="nav-item">
          <a href="/#contact">
            
            <span>Contact</span>
            
          </a>
        </li>

        
        
      

      
      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/Event">

  


  <div class="article-container">

    <div class="pub-title">
      <h1 itemprop="name">Evolvement of assurance over the lifecycle of several Phase 3 trials in a large oncology clinical development program</h1>
      <span class="pub-authors" itemprop="author">
        
      </span>
      <span class="pull-right">
        
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=Evolvement%20of%20assurance%20over%20the%20lifecycle%20of%20several%20Phase%203%20trials%20in%20a%20large%20oncology%20clinical%20development%20program&amp;url=https%3a%2f%2fnumbersman77.netlify.com%2ftalk%2finvited%2f2017_3_vienna_cen%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u=https%3a%2f%2fnumbersman77.netlify.com%2ftalk%2finvited%2f2017_3_vienna_cen%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-facebook"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https%3a%2f%2fnumbersman77.netlify.com%2ftalk%2finvited%2f2017_3_vienna_cen%2f&amp;title=Evolvement%20of%20assurance%20over%20the%20lifecycle%20of%20several%20Phase%203%20trials%20in%20a%20large%20oncology%20clinical%20development%20program"
         target="_blank" rel="noopener">
        <i class="fa fa-linkedin"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=https%3a%2f%2fnumbersman77.netlify.com%2ftalk%2finvited%2f2017_3_vienna_cen%2f&amp;title=Evolvement%20of%20assurance%20over%20the%20lifecycle%20of%20several%20Phase%203%20trials%20in%20a%20large%20oncology%20clinical%20development%20program"
         target="_blank" rel="noopener">
        <i class="fa fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=Evolvement%20of%20assurance%20over%20the%20lifecycle%20of%20several%20Phase%203%20trials%20in%20a%20large%20oncology%20clinical%20development%20program&amp;body=https%3a%2f%2fnumbersman77.netlify.com%2ftalk%2finvited%2f2017_3_vienna_cen%2f">
        <i class="fa fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


      </span>
    </div>

    
      <h3>Abstract</h3>
      <p class="pub-abstract" itemprop="text">Obinutuzumab is a second-generation anti-CD20 antibody targeted to improve outcome in three major lymphoma indications. In 2011, Roche launched a full development program for Obinutuzumab with four randomized Phase 3 trials, all with progression-free survival (PFS) as primary endpoint. Each of these trials compared Obinutuzumab plus an indication-specific chemotherapy against the standard of care, Rituximab plus the same chemotherapy. At the time, only a preliminary analysis of a randomized Phase 2 study in one of the indications comparing monotherapy only and assessing response instead of PFS was available. We discuss how an initial assesssment of Bayesian Predictive Power (BPP) was put together in this setup, by synthesizing information on the response-PFS association and prior assumptions. We further illustrate how this initial BPP was then updated (or not) at key study or program milestones such as read-out of one of the trials in another indication or not stopping a trial at a futility or efficacy interim analyses. BPP is generally used to inform the probability of success (PoS), a number with wide-ranging impact in our company such as valuation of the pipeline, gating of decisions by senior management, planning manufacturing capacity, or allocation of resources. We conclude by sharing experiences and recommendations on how to manage and communicate PoS updating throughout an entire development program.</p>
    

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Date</div>
          <div class="col-xs-12 col-sm-9" itemprop="datePublished">
            
            Aug 31, 2017
            <div class="talk-time">
              
                00:00
                
                  &mdash; 00:00
                
              
            </div>
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Event</div>
          <div class="col-xs-12 col-sm-9">
            <a href="http://www.cenisbs2017.org/" target="_blank" rel="noopener">
            Joint Meeting of the International Biometric Society Austro-Swiss, German, and Polish Region (invited talk)
            </a>
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Location</div>
          <div class="col-xs-12 col-sm-9">Vienna, Austria</div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    

    <div class="space-below"></div>

    <div class="article-style">
      <!-- Embed your slides or video here using [shortcodes](https://sourcethemes.com/academic/post/writing-markdown-latex/). Further details can easily be added using *Markdown* and $\rm \LaTeX$ math code. -->

    </div>

    


  </div>
</div>

<div class="container">
  <nav>
  <ul class="pager">
    
    <li class="previous"><a href="https://numbersman77.netlify.com/talk/invited/2019_2_basel_bbs/"><span
      aria-hidden="true">&larr;</span> External controls in drug development (with Hans Ulrich Burger)</a></li>
    

    
    <li class="next"><a href="https://numbersman77.netlify.com/talk/invited/2016_2_basel_bbs/">Event projection: quantify  uncertainty and manage expectations of broader teams <span
      aria-hidden="true">&rarr;</span></a></li>
    
  </ul>
</nav>

</div>

<footer class="site-footer">
  <div class="container">
    <p class="powered-by">

      &copy; 2019 &middot; 

      Powered by the
      <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
      <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

      <span class="pull-right" aria-hidden="true">
        <a href="#" id="back_to_top">
          <span class="button_icon">
            <i class="fa fa-chevron-up fa-2x"></i>
          </span>
        </a>
      </span>

    </p>
  </div>
</footer>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close btn-large" data-dismiss="modal">&times;</button>
        <h4 class="modal-title">Cite</h4>
      </div>
      <div>
        <pre><code class="modal-body tex"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-primary btn-outline js-copy-cite" href="#" target="_blank">
          <i class="fa fa-copy"></i> Copy
        </a>
        <a class="btn btn-primary btn-outline js-download-cite" href="#" target="_blank">
          <i class="fa fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    

    

    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js" integrity="sha512-3P8rXCuGJdNZOnUx/03c1jOTnMn3rP63nBip5gOP2qmUh5YAdVAvFZ1E+QLZZbC1rtMrQb+mah3AfYW11RUrWA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha512-iztkobsvnjKfAtTNdHkGVjAYTrrtlC7mGp/54c40wowO7LhURYl3gVzzcEqGl/qKXQltJ2HwMrdLcNUdo+N/RQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
    
    
    <script src="/js/hugo-academic.js"></script>
    

    
    
      
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
      

      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/r.min.js"></script>
      

      

      <script>hljs.initHighlightingOnLoad();</script>
    

    
    
    <script type="text/x-mathjax-config">
        MathJax.Hub.Config({ tex2jax: { inlineMath: [['$','$'], ['\\(','\\)']] } });
    </script>
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS_CHTML" integrity="sha512-tOav5w1OjvsSJzePRtt2uQPFwBoHt1VZcUq8l8nm5284LEKE9FSJBQryzMBzHxY5P0zRdNqEcpLIRVYFNgu1jw==" crossorigin="anonymous"></script>
    
    

  </body>
</html>

